MARKET

TTIPF

TTIPF

Thiogenesis
OTCMQB
0.400
NaN%
Closed 09:30 10/30 EDT
OPEN
--
PREV CLOSE
0.400
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.450
52 WEEK LOW
0.367
MARKET CAP
27.99M
P/E (TTM)
-4.5662
1D
5D
1M
3M
1Y
5Y
1D
Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis
Newsfile · 10/22 09:00
Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update
Newsfile · 09/21 08:00
Thiogenesis Engages Brisco Capital for Investor Relations
Newsfile · 09/03 10:00
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
Newsfile · 07/13 10:00
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
Newsfile · 06/17 12:00
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
Newsfile · 06/03 10:00
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
Newsfile · 06/01 18:49
Thiogenesis Announces Non-Brokered Private Placement
Newsfile · 05/11 13:00
More
About TTIPF
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Webull offers Thiogenesis Therapeutics Corp stock information, including OTCMQB: TTIPF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTIPF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TTIPF stock methods without spending real money on the virtual paper trading platform.